Viimeisimmät artikkelit
- Desentum’s UPSIT study with birch pollen allergy treatment DM-101PX approved by Paul-Ehrlich-Institut in Germany
- Desentum raises €28 million to develop safer, more effective allergen immunotherapy
- New peer-reviewed publication on Desentum’s investigational birch pollen allergen immunotherapy DM-101PX
- Desentum to present at the 2026 EAACI annual congress in Istanbul this week
- Desentum’s 18 M€ share issue from private investors and family offices breaks a record for unlisted growth companies in Finland
Viimeisimmät kommentit
No comments to show.